Work

Combating Bacterial Infections with Novel Small-Molecule Therapeuticals – Target Identification, Assay Development and Compound Screening

Year: 2015
Type: dissertation
Abstract: Graph A illustrates data collected from hospital intensive care units that participated in the National Nosocomial Infections Surveillance System of the Centers for Disease Control.6 MRSA: Methicillinresistant S. aureus; VRE: Vancomycin-resistant Enterococci; FQRP: Fluoroquinolone-resistant P. aeruginosa Graph B depicts the number of new molecular entity systemic antibiotic per 5-year interval.(Data taken from Infectious Diseases Society of America (IDSA), 20115)There are classes of antimicrobials that present a comparably slow rate of resistance development due to the fact that multiple targets are being addressed.This prevents fast endogenous resistance development by a single genetic change leading to reduced target affinity or cell permeability, or by up-regulating endogenous enzymes capable of inactivating the compound.7 As multiple steps of mutation and selection might be needed to lead to infection persistence in this case, a prolonged Market introduction (white) of novel anti-bacterials is followed by clinically significant resistance (red) depending on multiple factors.(Adapted from Nugent, 2010 14 ) Despite many discovery programs in pharmaceutical companies and academia, there is a void in the discovery of novel antibacterial drug classes since 1987 (Figure 3).Even though, several new drugs have been approved since.These were either described and patented before, or represent improved versions of previously registered classes.Improvements mainly addressed aspects of safety, bacterial spectrum, dosing regimens and most importantly, circumventing existing resistances and restoring antimicrobial activity.This route may be practicable due to the already suitable pharmacological properties of the known antibacterial.However, regulatory difficulties may arise due to the need of Augmentin by Beecham Pharmaceuticals, patent document GB 2 005 538 A 18 ).This therapy led to mechanism-based inhibition of -lactamase-conferred resistance and restored the -lactam efficacy.19 The newest addition to the -lactamase inhibitor combination therapy is Avibactam 20 , which is a non--lactam Serine--lactamase inhibitor.It was approved by the FDA in combination with Ceftazidime 21 as treatment for complicated urinary tract and intra-abdominal infections in February 2015.pathogens in the iron-depleted host environment.Here, siderophores (catecholates, hydroxamates, and citrate based poly-carboxylates) are agents selectively recognized for iron uptake.They can be reasonably coupled to antibacterial drugs.This strategy can overcome membrane-mediated resistances due to selective drug uptake.23 Basilea (BAL30072) and Pfizer (MC-1) develop siderophore-coupled monobactams against multi-drug resistant gram-negative pathogens.17 Apart from those advancements, an essential issue that hinders antibacterial drug development is posed by dormant persister cells, which cannot be addressed with most of the marketed antibiotics and can lead to re-occurence of the infection after treatment.This problem can be approached by prodrugs that are selectively activated by specific enzymes inside the bacterial cell and that are then able to kill even non-replicating cells.22 Isoniazide and ethionamide are examples of such prodrugs selective for a specific pathogen, in this case M. tuberculosis.24 Identification of produg-like compounds is usually prevented by the common validation step of drug specificity.Thus, particular effort is needed to find these promising compounds in suitable screenings.22 Inhibition of adhesion and colonization has been experimentally achieved by interfering with pili formation and the type III secretion system of Gram-negative pathogens (Chlamydia, E. coli, Pseudomonas, Salmonella, Shigella, Yersinia) with which effectors are directly injected into host cells to enable colonization.35,36 Another possibility is to block the secretion of cell surface associated factors, which can be achieved via Sortase inhibition (chapter 3.3.4)or by targeting enzymes involved in their biosynthesis as has been done with siderophores.Blocking of the domain salicylation enzymes from Mycobacterium tuberculosis and Yersinia pestis led to growth inhibition under ironlimiting conditions.37 Quorum sensing describes a complex bacterial signaling network, which regulates adaptation to changes in cell density and environment.In particular, crucial pathogenic mechanisms like resistance to the innate immune system as well as formation of surface-associated multi-cellular bacterial Colonization and InvasionS. aureus displays a wide variety of surface proteins.These are covalently attached to the bacterial cell-wall peptidoglycan and are crucially involved in commensal and pathogenic colonization.66 Up to 24 cell wall-anchored proteins can be encoded in a single strain 68 , whereas the expression pattern is also influenced by growth conditions like iron-limitation 69 .Nasal and epidermal colonization can be enabled by Clumping factor B (ClfB), the iron-regulated surface protein IsdA, and S. aureus surface protein X (SasX), which bind to squamous epithelialcells.70,71 As mentioned above, a well-studied source of S. aureus infections are injection needles and catheters.In these cases, perforation of the skin barrier may enable entry of S. aureus colonizing the dermis.52,53 However, biofilm formation on indwelling medical devices plays a major role in systemic infections with S. aureus.66 Biofilm formation is the pathogen's ability to manifest as multicellular Bacteria are generally classified on the anatomy of their cell envelope and specifically their peptidoglycan layer.126 It is much thicker in Gram-positive than in Gram-negative bacteria, leading to distinct staining phenotypes.127 Furthermore, Gram-positives possess only a cytoplasmic membrane and lack the LPS-rich outer membrane found in Gram-negatives.128 The thick peptidoglycan layer protects the Gram-positive bacteria from osmotic lysis and constitutes an effective barrier against hydrolases or membrane targeted toxins.126 The lack of an outer membrane implies direct secretion of signal-peptide bearing precursors to the extracellular space.129 Hence, a specific mechanism has
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2751427308
Cites: 247
Cited by: 1
Related to: 10